PL2405911T3 - Zastosowanie laktoli atorwastatyny jako leków - Google Patents
Zastosowanie laktoli atorwastatyny jako lekówInfo
- Publication number
- PL2405911T3 PL2405911T3 PL10709040T PL10709040T PL2405911T3 PL 2405911 T3 PL2405911 T3 PL 2405911T3 PL 10709040 T PL10709040 T PL 10709040T PL 10709040 T PL10709040 T PL 10709040T PL 2405911 T3 PL2405911 T3 PL 2405911T3
- Authority
- PL
- Poland
- Prior art keywords
- lactols
- atorvastatin
- medicaments
- atorvastatin lactols
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0904102.1A GB0904102D0 (en) | 2009-03-10 | 2009-03-10 | Use of atorvastatin lactols as medicaments |
EP10709040A EP2405911B1 (en) | 2009-03-10 | 2010-03-10 | Use of atorvastatin lactols as medicaments |
PCT/GB2010/050408 WO2010103319A1 (en) | 2009-03-10 | 2010-03-10 | Use of atorvastatin lactols as medicaments |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2405911T3 true PL2405911T3 (pl) | 2013-08-30 |
Family
ID=40600803
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL10709040T PL2405911T3 (pl) | 2009-03-10 | 2010-03-10 | Zastosowanie laktoli atorwastatyny jako leków |
Country Status (19)
Country | Link |
---|---|
US (1) | US20110319626A1 (pl) |
EP (1) | EP2405911B1 (pl) |
JP (1) | JP5738205B2 (pl) |
KR (1) | KR20110128193A (pl) |
CN (1) | CN102387799B (pl) |
AU (1) | AU2010222657B2 (pl) |
BR (1) | BRPI1008942A2 (pl) |
CA (1) | CA2754787A1 (pl) |
DK (1) | DK2405911T3 (pl) |
EA (1) | EA021034B1 (pl) |
ES (1) | ES2411095T3 (pl) |
GB (1) | GB0904102D0 (pl) |
IL (1) | IL215038A (pl) |
MX (1) | MX2011009457A (pl) |
NZ (1) | NZ595110A (pl) |
PL (1) | PL2405911T3 (pl) |
PT (1) | PT2405911E (pl) |
WO (1) | WO2010103319A1 (pl) |
ZA (1) | ZA201107054B (pl) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0904100D0 (en) | 2009-03-10 | 2009-04-22 | Bradford Pharma Ltd | Use of rosuvastatin lactols as medicaments |
GB0904104D0 (en) | 2009-03-10 | 2009-04-22 | Bradford Pharma Ltd | Atorvastatin and rosuvastatin derivatives |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
CA2530163C (en) | 2003-07-25 | 2012-10-02 | Avecia Pharmaceuticals Limited | Process and intermediate compounds useful in the preparation of statins, particularly atorvastatin |
GB0317393D0 (en) * | 2003-07-25 | 2003-08-27 | Avecia Ltd | Process and compounds |
GB0406757D0 (en) * | 2004-03-26 | 2004-04-28 | Avecia Ltd | Process and compounds |
DE102005022284A1 (de) * | 2005-05-13 | 2006-11-23 | Ratiopharm Gmbh | Verfahren zur Herstellung von Statinen |
EP1834944A1 (en) * | 2006-03-17 | 2007-09-19 | Ratiopharm GmbH | Process for preparing C7 intermediates and their use in the preparation on N-substituted pyrrole derivatives |
GB0904100D0 (en) * | 2009-03-10 | 2009-04-22 | Bradford Pharma Ltd | Use of rosuvastatin lactols as medicaments |
GB0904104D0 (en) * | 2009-03-10 | 2009-04-22 | Bradford Pharma Ltd | Atorvastatin and rosuvastatin derivatives |
-
2009
- 2009-03-10 GB GBGB0904102.1A patent/GB0904102D0/en not_active Ceased
-
2010
- 2010-03-10 MX MX2011009457A patent/MX2011009457A/es active IP Right Grant
- 2010-03-10 AU AU2010222657A patent/AU2010222657B2/en not_active Ceased
- 2010-03-10 PT PT107090409T patent/PT2405911E/pt unknown
- 2010-03-10 KR KR1020117023588A patent/KR20110128193A/ko not_active Application Discontinuation
- 2010-03-10 EA EA201101193A patent/EA021034B1/ru not_active IP Right Cessation
- 2010-03-10 BR BRPI1008942A patent/BRPI1008942A2/pt not_active IP Right Cessation
- 2010-03-10 ES ES10709040T patent/ES2411095T3/es active Active
- 2010-03-10 DK DK10709040.9T patent/DK2405911T3/da active
- 2010-03-10 NZ NZ595110A patent/NZ595110A/xx not_active IP Right Cessation
- 2010-03-10 PL PL10709040T patent/PL2405911T3/pl unknown
- 2010-03-10 JP JP2011553526A patent/JP5738205B2/ja not_active Expired - Fee Related
- 2010-03-10 WO PCT/GB2010/050408 patent/WO2010103319A1/en active Application Filing
- 2010-03-10 US US13/255,707 patent/US20110319626A1/en not_active Abandoned
- 2010-03-10 CA CA2754787A patent/CA2754787A1/en not_active Abandoned
- 2010-03-10 EP EP10709040A patent/EP2405911B1/en not_active Not-in-force
- 2010-03-10 CN CN201080016151.6A patent/CN102387799B/zh not_active Expired - Fee Related
-
2011
- 2011-09-08 IL IL215038A patent/IL215038A/en not_active IP Right Cessation
- 2011-09-27 ZA ZA2011/07054A patent/ZA201107054B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA201107054B (en) | 2014-03-26 |
CN102387799A (zh) | 2012-03-21 |
IL215038A (en) | 2014-06-30 |
WO2010103319A1 (en) | 2010-09-16 |
EA201101193A1 (ru) | 2012-04-30 |
AU2010222657B2 (en) | 2014-10-02 |
EA021034B1 (ru) | 2015-03-31 |
ES2411095T3 (es) | 2013-07-04 |
GB0904102D0 (en) | 2009-04-22 |
KR20110128193A (ko) | 2011-11-28 |
JP5738205B2 (ja) | 2015-06-17 |
DK2405911T3 (da) | 2013-06-10 |
EP2405911B1 (en) | 2013-03-06 |
EP2405911A1 (en) | 2012-01-18 |
JP2012520280A (ja) | 2012-09-06 |
CN102387799B (zh) | 2015-07-22 |
US20110319626A1 (en) | 2011-12-29 |
CA2754787A1 (en) | 2010-09-16 |
AU2010222657A1 (en) | 2011-09-29 |
BRPI1008942A2 (pt) | 2016-03-15 |
NZ595110A (en) | 2013-02-22 |
PT2405911E (pt) | 2013-06-05 |
MX2011009457A (es) | 2012-04-10 |
IL215038A0 (en) | 2011-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1231408A1 (zh) | 藥物組合物 | |
PT2482812T (pt) | Composições farmacêuticas compreendendo bi-1356 e metformina | |
ZA201200054B (en) | Therapeutic compounds and compositions | |
ZA201107053B (en) | Use of rosuvastatin lactols as medicaments | |
EP2451274A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
ZA201108901B (en) | Compounds useful as medicaments | |
EP2419097A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
EP2500038A4 (en) | PHATMACEUTICAL COMPOSITION FOR EXTERNAL USE / | |
EP2379077A4 (en) | PHARMACEUTICAL COMPOSITION | |
ZA201106703B (en) | Use of pharmaceutical compositions containing mesembrenone | |
EP2341773A4 (en) | PHARMACEUTICAL COMPOSITIONS FROM ATORVASTATIN | |
EP2515880A4 (en) | NEW PHARMACEUTICAL COMPOSITIONS OF RANOLAZINE | |
ZA201107054B (en) | Use of atorvastatin lactols as medicaments | |
GB0922023D0 (en) | Preparation of n-monofluoroalkyl compounds | |
EP2488175A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
HK1131039A1 (en) | Pharmaceutical use of sophoricoside | |
GB0900786D0 (en) | Therapeutic compositions | |
PT2471520T (pt) | Composições farmacêuticas de levetiracetam | |
PL2407159T3 (pl) | Kompozycje farmaceutyczne olmesartanu | |
PL2277511T3 (pl) | Kompozycje farmaceutyczne lewetiracetamu o przedłużonym uwalnianiu | |
GB0917775D0 (en) | Novel pharmaceutical compounds | |
GB0919650D0 (en) | Pharmaceutical composition | |
EP2331490A4 (en) | PREPARATION OF DIBUTOXYMETHANE | |
EP2459540A4 (en) | PREPARATION OF FIPAMEZOLE | |
ZA201200531B (en) | Pharmaceutical composition of rifampicin |